Corrigendum: Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

Corrigendum: Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

Saved in:

Bibliographic Details
Main Authors:	Fengqi Zhou, Haiou He, Jing Gao, Zhen Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Series:	Frontiers in Pharmacology
Subjects:	dizziness postoperative analgesia FAERS drug safety signal detection
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1586073/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database
by: Fengqi Zhou, et al.
Published: (2025-02-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)

Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2025-05-01)

Hepatobiliary Adverse Events Associated with Pembrolizumab: A Pharmacovigilance Study from the FDA Adverse Event Reporting System (FAERS) Database
by: Connor Frey
Published: (2024-12-01)

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system
by: Haolin Teng, et al.
Published: (2025-05-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database
by: Huiling Zhang, et al.
Published: (2025-07-01)

A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database
by: Chunyue Fang, et al.
Published: (2025-06-01)

Analysis and mining of L-ornithine L-aspartate adverse events based on FAERS database
by: Hui Zhang, et al.
Published: (2025-07-01)

Analysis and mining of Dupilumab adverse events based on FAERS database
by: Hui Gao, et al.
Published: (2025-03-01)

Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system
by: Cheng Jiang, et al.
Published: (2025-07-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database
by: Hunong Xiang, et al.
Published: (2025-01-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database
by: Yu Lin, et al.
Published: (2025-08-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database
by: Xiang Li, et al.
Published: (2025-04-01)

Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database
by: Juan Su, et al.
Published: (2025-07-01)

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01)

Signal mining and risk analysis of olanzapine adverse events in the FAERS database
by: Aiguo Dong, et al.
Published: (2025-07-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab
by: Linlin Yan, et al.
Published: (2025-04-01)

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
by: Yaqian Tan, et al.
Published: (2025-08-01)

A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System
by: Dongdong Zhang, et al.
Published: (2024-12-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
by: Zhong Xue, et al.
Published: (2024-11-01)

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database
by: Yunlin Yang, et al.
Published: (2025-04-01)

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Pan Ding, et al.
Published: (2025-03-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system
by: Chufeng Ding, et al.
Published: (2025-04-01)

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
by: Yongfu Song, et al.
Published: (2025-03-01)

Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System
by: Si-Yuan Hong, et al.
Published: (2025-07-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)